Durvalumab (NCT04918186)

Name: Durvalumab trial for Ovarian Cancer (NCT04918186)
Uploaded: 2026-10-31T21:28:11.374Z
Duration: 1 min 12 s
Description: Durvalumab trial for Ovarian Cancer (NCT04918186). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04918186.

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer: a one-minute explainerNCT049181861 min

Durvalumab trial for Ovarian Cancer (NCT04918186). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with high-grade serous ovarian, fallopian-tube, or peritoneal cancer progressing within six months of platinum treatment. At most one chemotherapy regimen for platinum-resistant disease is allowed. Measurable disease and tumor biopsies are required.

The idea: the open arm combines intravenous ENB-003, which blocks endothelin-B signaling linked to immune suppression, with toripalimab, which releases the PD1 immune brake. Researchers assess tumor response. Two durvalumab combination arms are closed.

This phase 2 study plans 60 patients. Canadian Cancer Trials Group sponsors; University of Chicago is the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.